News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premiumhere.

Moody's Investor Service commented that Eli Lilly and Company's (NYSE: LLY) announcement that its experimental Alzheimer's disease drug solanezumab did not meet the endpoint in a Phase III trial is credit negative. There is no effect on Lilly's A2 rating or stable rating outlook.